PL3393510T3 - Szczepionka przeciwko wirusowi zika - Google Patents

Szczepionka przeciwko wirusowi zika

Info

Publication number
PL3393510T3
PL3393510T3 PL16828746.4T PL16828746T PL3393510T3 PL 3393510 T3 PL3393510 T3 PL 3393510T3 PL 16828746 T PL16828746 T PL 16828746T PL 3393510 T3 PL3393510 T3 PL 3393510T3
Authority
PL
Poland
Prior art keywords
zika virus
virus vaccine
vaccine
zika
virus
Prior art date
Application number
PL16828746.4T
Other languages
English (en)
Inventor
Jana BARBERO CALZADO
Mario NEBENFÜHR
Robert Schlegl
Michael Weber
Jürgen WRUSS
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3393510(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of PL3393510T3 publication Critical patent/PL3393510T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16828746.4T 2015-12-23 2016-12-23 Szczepionka przeciwko wirusowi zika PL3393510T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP16161068 2016-03-18
EP16176025 2016-06-23
EP16176049 2016-06-23
EP16182845 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (1)

Publication Number Publication Date
PL3393510T3 true PL3393510T3 (pl) 2023-06-26

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16828746.4T PL3393510T3 (pl) 2015-12-23 2016-12-23 Szczepionka przeciwko wirusowi zika

Country Status (19)

Country Link
US (14) US11331382B2 (pl)
EP (9) EP3393509B1 (pl)
JP (1) JP6949027B2 (pl)
KR (1) KR102950500B1 (pl)
CN (2) CN115381934A (pl)
AU (1) AU2016375338B2 (pl)
BR (1) BR112018012873A2 (pl)
CA (1) CA3009278A1 (pl)
DK (1) DK3393510T5 (pl)
ES (4) ES2950887T3 (pl)
FI (1) FI3393510T3 (pl)
HR (1) HRP20230273T1 (pl)
HU (1) HUE061679T2 (pl)
LT (1) LT3393510T (pl)
MX (1) MX2018007627A (pl)
PL (1) PL3393510T3 (pl)
SG (1) SG11201805120YA (pl)
SI (1) SI3393510T1 (pl)
WO (6) WO2017109227A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
UA126548C2 (uk) * 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2020004543A (es) * 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
CN116983398A (zh) * 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
MX420109B (es) 2018-03-26 2025-02-10 Boehringer Ingelheim Animal Health Usa Inc Metodo para producir una composicion inmunogenica
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
AU2020211990A1 (en) * 2019-01-22 2021-08-12 2Seventy Bio, Inc. Methods and systems for manufacturing viral vectors
EP3965811A1 (en) * 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
WO2021028407A1 (en) 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
IL290458B2 (en) 2019-08-09 2025-06-01 Valneva Se Chikungunya vaccine formulations
WO2021048221A1 (en) * 2019-09-09 2021-03-18 Valneva Austria Gmbh Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
EP4114456A1 (en) 2020-03-06 2023-01-11 The Colorado State University Research Foundation Production of vaccines comprising inactivated sars-cov-2 viral particles
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン，インコーポレイテッド 抗原の効力を決定するための方法
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
US20250381261A1 (en) * 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
EP1025209B1 (en) * 1997-08-28 2007-02-28 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
DE69942525D1 (de) * 1998-09-02 2010-08-05 Us Government Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
EP2073839B1 (en) * 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
CA2721870C (en) * 2008-04-21 2020-12-22 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
WO2010062396A2 (en) * 2008-11-26 2010-06-03 Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
ES2647882T3 (es) 2011-12-06 2017-12-27 Valneva Austria Gmbh Compuestos de aluminio para su uso en productos terapéuticos y vacunas
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3

Also Published As

Publication number Publication date
JP2019504030A (ja) 2019-02-14
EP4253403A3 (en) 2023-12-27
CN108697785A (zh) 2018-10-23
EP3393508A1 (en) 2018-10-31
ES2973267T3 (es) 2024-06-19
US20220273786A1 (en) 2022-09-01
US11219681B2 (en) 2022-01-11
EP3393506A1 (en) 2018-10-31
CN115381934A (zh) 2022-11-25
EP3393508B1 (en) 2023-06-07
EP3393507A1 (en) 2018-10-31
EP3393509B1 (en) 2024-02-28
EP4218807A3 (en) 2023-09-06
US12102673B2 (en) 2024-10-01
US20200384099A1 (en) 2020-12-10
WO2017109223A1 (en) 2017-06-29
HRP20230273T1 (hr) 2023-04-28
EP3393510B1 (en) 2023-02-22
WO2017109228A1 (en) 2017-06-29
US11524064B2 (en) 2022-12-13
US20180362936A1 (en) 2018-12-20
US20200017555A9 (en) 2020-01-16
WO2017109224A1 (en) 2017-06-29
EP3393506C0 (en) 2024-03-13
MX2018007627A (es) 2019-02-14
AU2016375338A1 (en) 2018-07-05
WO2017109229A1 (en) 2017-06-29
US20250018023A1 (en) 2025-01-16
DK3393510T3 (da) 2023-03-13
US10744194B2 (en) 2020-08-18
EP3393508C0 (en) 2023-06-07
DK3393510T5 (da) 2024-09-30
US20190008945A1 (en) 2019-01-10
EP3393506B1 (en) 2024-03-13
EP3393510A1 (en) 2018-10-31
EP3393507C0 (en) 2024-02-07
US20200197506A1 (en) 2020-06-25
US20200368342A1 (en) 2020-11-26
EP3393507B1 (en) 2024-02-07
ES2941967T3 (es) 2023-05-29
EP3393509A1 (en) 2018-10-31
WO2017109225A1 (en) 2017-06-29
US11331382B2 (en) 2022-05-17
AU2016375338B2 (en) 2021-11-04
US11207397B2 (en) 2021-12-28
US20230226165A1 (en) 2023-07-20
EP4253403A2 (en) 2023-10-04
EP3393508B9 (en) 2023-09-27
EP4218807A2 (en) 2023-08-02
US12005111B2 (en) 2024-06-11
CN108697785B (zh) 2022-08-02
EP4393938A2 (en) 2024-07-03
EP4357355A3 (en) 2024-09-25
JP6949027B2 (ja) 2021-10-20
US11951163B2 (en) 2024-04-09
LT3393510T (lt) 2023-03-27
KR20180097558A (ko) 2018-08-31
ES2976311T3 (es) 2024-07-29
US20230056142A1 (en) 2023-02-23
BR112018012873A2 (pt) 2018-12-04
US12214033B2 (en) 2025-02-04
HUE061679T2 (hu) 2023-08-28
ES2950887T3 (es) 2023-10-16
CA3009278A1 (en) 2017-06-29
US20180371027A1 (en) 2018-12-27
KR102950500B1 (ko) 2026-04-08
US20180362937A1 (en) 2018-12-20
WO2017109227A1 (en) 2017-06-29
US11406700B2 (en) 2022-08-09
US10639365B2 (en) 2020-05-05
SG11201805120YA (en) 2018-07-30
EP3393509C0 (en) 2024-02-28
US20210093707A1 (en) 2021-04-01
FI3393510T3 (fi) 2023-03-22
US20180369359A1 (en) 2018-12-27
SI3393510T1 (sl) 2023-04-28
US10660950B2 (en) 2020-05-26
US20240108712A1 (en) 2024-04-04
EP4357355A2 (en) 2024-04-24
EP4393938A3 (en) 2024-08-07
US10537630B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
LT3393510T (lt) Zikos viruso vakcina
SG10201913630YA (en) Zika virus vaccine
ZA201804071B (en) Recombinant zika vaccines
IL258831A (en) Assemble respiratory syncytial virus
SMT202200361T1 (it) Vaccini contro virus respiratori
SG11201803474UA (en) Vaccines against hepatitis b virus
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201518684D0 (en) Vaccine
GB201613191D0 (en) Zika virus vaccine
GB201410971D0 (en) Vaccine
GB201405834D0 (en) Oncolytic virus
GB201406608D0 (en) Virus
ES2648672T5 (en) Improved hvt-vectored nd-ibd vaccine
SG11201610443WA (en) Influenza virus vaccines and uses thereof
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
GB201506041D0 (en) Avian vaccine
ZA201608436B (en) Live attenuated african horsesickness virus
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
PT3393510T (pt) Vacina contra o vírus zika
GB201522013D0 (en) Virus
GB201516936D0 (en) Virus
IL249705B (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses